secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105024
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q2 net loss widens to $66.1M; FDA sets Nov 30 PDUFA for ziftomenib NDA
--------------------------------------------------------------------------------

- Net loss $66.1M in Q2 2025 vs $50.8M in Q2 2024; collaboration revenue $15.3M from Kyowa Kirin.
- FDA Priority Review for ziftomenib NDA; PDUFA target action date Nov 30, 2025.
- Cash, equivalents and investments $630.7M as of June 30; expected to fund operations into 2027, plus Kyowa Kirin funding.
- Phase 3 KOMET-017 trials and first KO-2806/FTI data expected in 2H 2025 at ESMO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/0000950170-25-105024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017025105024/kura-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer